Rockwell Medical, Inc.
- Jurisdiction
United States - LEI
529900Y6YUB5X93MMD77 - ISIN
US7743743004 (RMTI )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. Read full profile
Stock price
Fundamentals
- Net revenue
€75.51M - Gross margin
17.5% - EBIT
-€1.11M - EBIT margin
-1.5% - Net income
-€1.80M - Net margin
-2.4%
Statement period: - (published )
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: May 14, 2024
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |